Bristol-Myers' Phase III lung cancer trial of Opdivo stopped early
Bristol-Myers Squibb (BMS) has stopped its open-label, randomised Phase III trial (CheckMate -017) evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Squamous Cell Carcinoma | Taxotere